Evoke Pharma, Inc. (EVOK)
NASDAQ: EVOK · Real-Time Price · USD
5.13
-0.08 (-1.54%)
Oct 24, 2024, 4:00 PM EDT - Market closed
Company Description
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases.
It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers.
Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Evoke Pharma, Inc.
| Country | United States |
| Founded | 2007 |
| IPO Date | Sep 25, 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Matthew D'Onofrio |
Contact Details
Address: 420 Stevens Avenue, Suite 230 Solana Beach, California 92075 United States | |
| Phone | 858 345 1494 |
| Website | evokepharma.com |
Stock Details
| Ticker Symbol | EVOK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001403708 |
| CUSIP Number | 30049G104 |
| ISIN Number | US30049G2030 |
| Employer ID | 20-8447886 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew J. D'Onofrio MBA | Co-Founder, Chief Executive Officer and Director |
| Dr. Marilyn R. Carlson D.M.D., M.D., RAC. | Chief Medical Officer |
| Mark A. Kowieski CPA | Chief Financial Officer |
| Christopher Quesenberry | Chief Commercial Officer - Gimoti (TM) |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2024 | 8-K | Current Report |
| Oct 17, 2024 | 8-K | Current Report |
| Oct 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Sep 27, 2024 | 424B3 | Prospectus |
| Sep 27, 2024 | 8-K | Current Report |
| Sep 20, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Sep 6, 2024 | EFFECT | Notice of Effectiveness |
| Sep 3, 2024 | UPLOAD | Filing |
| Aug 29, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 21, 2024 | EFFECT | Notice of Effectiveness |